Cytokinetics Announces Nine Upcoming Presentations at the European Society of Cardiology Heart Failure 2026 Congress
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced nine presentations at the European Society of Cardiology Heart Failure 2026 Congress taking place in Barcelona, Spain, from May 9–12, 2026. Eight presentations, including a late-breaking science oral presentation, are related to MYQORZO® (aficamten). Recently approved for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) by the U.S. Food and Drug Administration, European Commission, and the China National Medical Products Administration, MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and consequently, left ventricular outflow tract (LVOT) obstruction. Late Breaking Science Oral Presentation Title: Dose-dependent effects of aficamten compared with metoprolol in obstructive HCM: the MAPLE-HCM studyPresenter
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- How Cytokinetics Defied Biotech’s Odds To Reach FDA Approval [Forbes]Forbes
- Cytokinetics: Strong Story, But Valuation Leaves Limited Upside [Seeking Alpha]Seeking Alpha
- Cytokinetics (CYTK) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Cytokinetics to Announce First Quarter Results on May 5, 2026GlobeNewswire
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)GlobeNewswire
CYTK
Earnings
- 2/24/26 - Miss
CYTK
Sec Filings
- 4/29/26 - Form SCHEDULE
- 4/29/26 - Form 4
- 4/21/26 - Form 4
- CYTK's page on the SEC website